Tue07292014

Last updateTue, 29 Jul 2014 2pm

Back You are here: Home News Industry Headlines Valve Manufacturing Crane Co. Reports Fourth Quarter Results; Posts Record EPS in 2012

Valve Manufacturing

Crane Co. Reports Fourth Quarter Results; Posts Record EPS in 2012

Crane Co. reported fourth quarter 2012 earnings from continuing operations of $0.79 per share, compared to a net loss of $2.18 per share in the fourth quarter of 2011. Fourth quarter 2012 results included after-tax charges of $4 million, or $0.07 per share, associated with previously announced repositioning actions, as well as transaction-related costs of $4 million, or $0.07 per share.

Fourth quarter 2012 sales from continuing operations of $630 million increased $10 million, or 1.6%, compared to the fourth quarter of 2011, resulting entirely from core sales growth. Operating profit from continuing operations in the fourth quarter of 2012 was $76.2 million compared to an operating loss of $194.0 million in the fourth quarter of 2011. Excluding Special Items, fourth quarter 2012 operating profit from continuing operations increased 8.5% to $84.6 million compared to $78.0 million in the fourth quarter of 2011, and operating profit margin increased to 13.4%, compared to 12.6% in the fourth quarter of 2011.

Fourth quarter 2012 sales in the Fluid Handling segment declined $2.5 million, or 1%, driven primarily by weaker European end markets. Segment operating margin improved to 13.9%, reflecting improved execution, productivity gains and solid cost management. Fluid Handling order backlog was $327 million at December 31, 2012, compared to $331 million at September 30, 2012 and $314 million at December 31, 2011.

New Products

 

Valve Magazine Digital Edition

14 SUM CVR 160x214Inside the Summer 2014 issue…

• Attracting Talent
• Advances in Machining
• Severe Service in Power Plants
• SIS Tests and Standards

CLICK HERE TO REQUEST YOUR
DIGITAL EDITION PREVIEW EMAIL

arimidex or nolvadex testerone cypionate dosage buy steroids in usa online how to take steroids best injectable steroids market